Orthocell Ltd (ASX: OCC) shares are catching the eye on Wednesday morning.
In early trade, the ASX All Ords stock is up 5% to 82 cents.
Image source: Getty Images
Why are Orthocell shares rising today?
The company's shares are pushing higher today following the release of an announcement that highlights the real-world use of its Remplir device in a conflict setting.
Remplir is a collagen nerve wrap used in the repair of peripheral nerve injuries. It provides compression-free protection to the nerve, generating an ideal microenvironment to aid nerve healing.
According to the release, the ASX All Ords stock's Remplir product has been used in 23 surgical procedures on injured soldiers in Ukraine.
The company confirmed that the procedures followed a humanitarian delivery of the device to Ukraine in April 2025, with surgeons now successfully using Remplir in both primary and secondary nerve repair operations.
The good news is that feedback from surgeons has been positive, supporting the clinical utility of the device.
Real-world validation in challenging environments
Management highlighted that this deployment demonstrates the practicality of Remplir in demanding conditions such as conflict zones.
The device is designed to connect, protect, and cap severed nerves resulting from trauma. Its portability, ease of use, and ability to be stored at room temperature make it well suited for use in military and emergency environments.
Importantly, Orthocell was able to train Ukrainian surgeons remotely via video, supported by its key opinion leader and Australian orthopedic surgeon, Dr Alex O'Beirne. The successful adoption of the product following remote instruction highlights its accessibility and ease of implementation in the field.
Defence opportunity emerging
The ASX All Ords stock believes this experience could open the door to further opportunities with defence organisations globally.
Orthocell intends to continue working with Ukrainian surgeons to monitor patient outcomes and collect clinical data where possible. This data is expected to support future discussions with defence and medical organisations around the world.
Commenting on the development, the company's managing director, Paul Anderson, said:
In a time where there are multiple global conflicts, the application of Remplir in trauma-related nerve injuries is highly relevant. The successful remote training of surgeons and subsequent use of the device across 23 patients reinforces its unique handling, transportability, and clinical utility as a leading collagen-based nerve repair solution.
